[Publication Report] Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government (March 31, 2024)
date : 4/4/2024
Health and Global Policy Institute (HGPI) has offered policy recommendations and taken a number of other activities to promote patient and public involvement (PPI) in policy development process, under our stated mission of “Achieving citizen-centered health policy.” Recently, initiatives for PPI in processes of health policy development are now being advanced at both the national Government and local level at councils. However, new issues have been recognized consequently, which include lack of the diversities in and the number of individuals who desire to be involved. Based on our recognition of these issues, our PPI Support Project this fiscal year aims to promote the involvement of diverse patient and public representatives into policy development process.
Based on our discussions to date, we have compiled a ” Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government.” This guidance reviews how PPI in the policymaking process is important and outlines the initiatives that are required in the future to promote it. Please refer to the PDF file at the end of this document for the details of this guide.
FY2023 Advisory Board Members (Titles omitted; in Japanese alphabetical order by last name, absent members included)
Kyoko Ama (Representative, Children and Healthcare Project; Fellow, HGPI)
Shinsuke Amano (Chair, The Japan Federation of Cancer Patient Groups; CEO, Group Nexus Japan)
Etsuko Aruga (Professor, Department of Palliative Medicine, Teikyo University School of Medicine)
Naomi Sakurai (President, Cancer Solutions Co., Ltd)
Takeshi Shukunobe (President and CEO, PPeCC)
Kazuyuki Suzuki (Senior Lead, Patient Engagement Group, Strategy & Execution, Novartis Pharma K.K.)
Yasuhiro Sensho (CEO, SENSHO-GUMI, Co., Ltd.; Former Director-General, MHLW)
Teppei Maeda (Lawyer, Maeda & Unosawa Law Offices; Representative, Medical Basic Act Community)
Kaori Muto (Professor, Department of Public Policy Studies, Institute of Medical Science, University of Tokyo)
Akira Morita (Representative Director, Next Generation Fundamental Policy Research Institute (NFI))
Ikuko Yamaguchi (Chief Director, Consumer Organization for Medicine and Law (COML))
Risa Yamazaki (Public Affairs Group, External Affairs Department, Chugai Pharmaceutical Co., LTD.)
Project sponsors (in Japanese alphabetical order)
National Graduate Institute for Policy Studies (GRIPS) Global Health Innovation Policy Program
Syneos Health Commercial K.K.
Chugai Pharmaceutical Co., Ltd.
Novartis Pharma K.K.
日本語
Top Research & Recommendations Posts
- [Announcement] HGPI Joins Alliance for Transformative Action on Climate and Health (April 22, 2024)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Publication Report] Developing and Expanding Cardiovascular Disease Control Plans in Each Prefecture – Challenges and Good Examples for Cardiovascular Disease Control (September 7, 2023)
- [Event Report] Planetary Health Expert Meeting Aiming for Sustainable Healthcare: Learning from the Impact of Environmental Pollution and Medical Waste During the Pandemic (February 16, 2024)
- [Public Comment Submission] Opinions Regarding the Proposed “National Action Plan on Antimicrobial Resistance 2023-2027 (Draft)” (March 16, 2023)
- [Publication Report] Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government (March 31, 2024)
Featured Posts
-
2024-04-22
[Registration Open] (Hybrid Format) Intractable Disease Day Symposium: Future Measures for Intractable Diseases from the Perspectives of Patients and Citizens (May, 23 2024)
-
2024-04-23
[Registration Open] (Webinar) The 125th HGPI Seminar: Progress and Prospects for Domestic Measures on Health Problems Caused by Alcohol (May 24 , 2024)
-
2024-04-30
[Event Report] Non-partisan Diet Member Briefing – 30-minute Health Policy Update: “Community Development for Senior Health: From Establishing Evidence to Social Implementation” (April 23, 2024)
-
2024-05-02
[Event Report] The 123rd HGPI Seminar – The Current Situation and Future Prospects for Epilepsy in Japan and Around the World (March 6, 2024)
-
2024-05-09
[Registration Open] The Health Policy Academy the 13th Session